<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1102256878
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2012
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ARBITEN 160MG FILM COATED TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VALSARTAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        160
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        32.5
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jordan Sweden Medical and Sterilization Co." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jordan Sweden Medical and Sterilization Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 679]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            AL-DAWAA MEDICAL SERVICES CO. LTD
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jordan Sweden Medical and Sterilization Co.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09CA03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>ARBITEN (Valsartan) belongs to a class of medicines known as angiotensin II receptor antagonists, which help to control high blood pressure. Angiotensin II is a substance in the body that causes vessels to tighten, thus causing your blood pressure to increase. Valsartan works by blocking the effect of angiotensin II. As a result, blood vessels relax and blood pressure is lowered.</p><p>ARBITEN Film Coated Tablets can be used:</p><p>&bull; to treat people after a recent heart attack (myocardial infarction). &ldquo;Recent&rdquo; here means between 12 hours and 10 days.</p><p>&bull; to treat symptomatic heart failure. ARBITEN is used when a group of medicines called Angiotensin Converting Enzyme (ACE) inhibitors (a medication to treat heart failure) cannot be used.</p><p>Heart failure symptoms include shortness of breath, and swelling of the feet and legs due to fluid build-up. It is caused when the heart muscle cannot pump blood strongly enough to supply all the blood needed throughout the body.</p><p>In addition</p><p>ARBITEN 80 and 160 mg Film Coated Tablets can be used:</p><p>&bull; to treat high blood pressure. High blood pressure increases the workload on the heart and arteries. If not treated it can damage the blood vessels of the brain, heart, and kidneys, and may result in a stroke, heart failure, or kidney failure. High blood pressure increases the risk of heart attacks. Lowering your blood pressure to normal reduces the risk of developing these disorders.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take ARBITEN:</p><p>&bull; if you are allergic (hypersensitive) to valsartan or any of the other ingredients of ARBITEN.</p><p>&bull; if you have severe liver disease.</p><p>&bull; if you are more than 3 months pregnant (it is also better to avoid ARBITEN in early pregnancy- see pregnancy section).</p><p>&bull;if you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine called aliskiren.</p><p>If any of these apply to you, speak to your doctor.</p><p>Take special care with ARBITEN:</p><p>&bull; If you have liver disease.</p><p>&bull; If you have severe kidney disease or if you are undergoing dialysis.</p><p>&bull; If you are suffering from a narrowing of the kidney artery.</p><p>&bull; If you have recently undergone kidney transplantation (received a new kidney).</p><p>&bull; If you are being treated after a heart attack or for heart failure. Your doctor may check your kidney function.</p><p>&bull; If you have severe heart disease other than heart failure or heart attack.</p><p>&bull; If you have history of angioedema.</p><p>&bull; If you are taking medicines that increase the amount of potassium in your blood. These include potassium supplements or salt substitutes containing potassium, potassium-sparing medicines and heparin. It may be necessary to check the amount of potassium in your blood at regular intervals.</p><p>&bull; If you suffer from aldosteronism. This is a disease in which your adrenal glands make too much of the hormone aldosterone. If this applies to you, the use of ARBITEN is not recommended.</p><p>&bull; If you have lost a lot of fluid (dehydration) caused by diarrhoea, vomiting, or high doses of water pills (diuretics).</p><p>&bull; The use of ARBITEN in children and adolescents below the age of 18 years is not recommended.</p><p>&bull; You must tell your doctor if you think you are (or might become) pregnant. ARBITEN is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section).</p><p>&bull; Combination therapy of ACEI and ARB drugs may cause an increased risk of hyperkalaemia, worsening of the kidney function and hypotension. Therefore, this combination should not be used, especially in patients with kidney problems.</p><p>Taking other medicines:</p><p>Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.</p><p>The effect of the treatment can be influenced if ARBITEN is taken together with certain other medicines. It may be necessary to change the dose, to take other precautions, or in some cases to stop taking one of the medicines. This applies to both prescription and non-prescription medicines, especially:</p><p>&bull; other medicines that lower blood pressure, especially water pills (diuretics).</p><p>&bull; medicines that increase the amount of potassium in your blood. These include potassium supplements or salt substitutes containing potassium, potassium-sparing medicines and heparin.</p><p>&bull; certain type of pain killers called non-steroidal anti-inflammatory medicines (NSAIDs).</p><p>&bull; some antibiotics (rifamycin group), a drug used to protect against transplant rejection (ciclosporin) or an antiretroviral drug used to treat HIV/AIDS infection (ritonavir). These drugs may increase the effect of ARBITEN.</p><p>&bull; lithium, a medicine used to treat some types of psychiatric illness.</p><p>&bull; other medicines to lower your blood pressure including methyldopa, water pills (diuretics), ACE inhibitors (such as enalapril, lisinopril, etc.) or aliskiren.</p><p>Taking ARBITEN with food and drink:</p><p>You can take ARBITEN with or without food.</p><p>Pregnancy and breast-feeding:</p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p>&bull; You must tell your doctor if you think that you are (or might become) pregnant. Your doctor will normally advise you to stop taking ARBITEN before you become pregnant or as soon as you know you are pregnant, and will advise you to take another medicine instead of ARBITEN. ARBITEN is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if it is used after the third month of pregnancy.</p><p>&bull; Tell your doctor if you are breast-feeding or about to start breast-feeding. ARBITEN is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.</p><p>Driving and using machines:</p><p>Before you drive a vehicle, use tools or operate machines, or carry out other activities that require concentration, make sure you know how Arbiten affects you. Like many other medicines used to treat high blood pressure, Arbiten may in rare cases cause dizziness and affect the ability to concentrate.</p><p>Important information about some of the ingredients of ARBITEN:</p><p>None.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take ARBITEN exactly as your doctor has told you in order to get the best results and reduce the risk of side effects. You should check with your doctor or pharmacist if you are not sure. People with high blood pressure often do not notice any signs of this problem. Many may feel quite normal. This makes it all the more important for you to keep your appointments with the doctor even if you are feeling well.</p><p>After a recent heart attack: After a heart attack the treatment is generally started as early as after 12 hours, usually at a low dose of 20 mg twice daily. Your doctor will increase this dose gradually over several weeks to a maximum of 160 mg twice daily. The final dose depends on what you as an individual patient can tolerate.</p><p>ARBITEN can be given together with other treatment for heart attack, and your doctor will decide which treatment is suitable for you.</p><p>Heart failure: Treatment starts generally with 40 mg twice daily. Your doctor will increase the dose gradually over several weeks to a maximum of 160 mg twice daily. The final dose depends on what you as an individual patient can tolerate.</p><p>ARBITEN can be given together with other treatments for heart failure, and your doctor will decide which treatment is suitable for you.</p><p>High blood pressure: The usual dose is 80 mg daily. In some cases your doctor may prescribe higher doses (e.g. 160 mg or 320 mg). He may also combine ARBITEN with an additional medicine (e.g. a diuretic).</p><p>You can take ARBITEN with or without food. Swallow ARBITEN with a glass of water.</p><p>Take ARBITEN at about the same time each day:</p><p>If you take more ARBITEN than you should:</p><p>If you experience severe dizziness and/or fainting, lie down and contact your doctor immediately.</p><p>If you have accidentally taken too many tablets, contact your doctor, pharmacist, or hospital.</p><p>If you forget to take ARBITEN:</p><p>Do not take a double dose to make up for a forgotten dose.</p><p>If you forget to take a dose, take it as soon as you remember. However, if it is almost time for your next dose, skip the dose you missed.</p><p>If you stop taking ARBITEN:</p><p>Stopping your treatment with ARBITEN may cause your disease to get worse. Do not stop taking your medicine unless your doctor tells you to.</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, ARBITEN can cause side effects, although not everybody gets them.</p><p>These side effects may occur with certain frequencies, which are defined as follows:</p><p>&bull; very common: affects more than 1 user in 10.</p><p>&bull; common: affects 1 to 10 users in 100.</p><p>&bull; uncommon: affects 1 to 10 users in 1,000.</p><p>&bull; rare: affects 1 to 10 users in 10,000.</p><p>&bull; very rare: affects less than 1 user in 10,000</p><p>&bull; not known: frequency cannot be estimated from the available data.</p><p>Some symptoms need immediate medical attention:</p><p>You may experience symptoms of angioedema, such as:</p><p>&bull; swollen face, tongue or throat.</p><p>&bull; difficulty in swallowing.</p><p>&bull; hives and difficulties in breathing.</p><p>If you get any of these symptoms, stop taking ARBITEN and contact your doctor straight away (see &ldquo;Take special care with ARBITEN&rdquo;).</p><p>Other side effects include:</p><p>Common:</p><p>&bull; dizziness, postural dizziness.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&bull; low blood pressure with or without symptoms such as dizziness and fainting when standing up.</p><p>&bull; decreased kidney function (signs of renal impairment).</p><p>Uncommon:</p><p>&bull; allergic reaction with symptoms such as rash, itching, dizziness, swelling of face or lips or tongue or throat, difficulty breathing or swallowing (signs of angioedema).</p><p>&bull; sudden loss of consciousness.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull; spinning sensation.</p><p>&bull; severely decreased kidney function (signs of acute renal failure).</p><p>&bull; muscle spasms, abnormal heart rhythm (signs of hyperkalaemia).</p><p>&bull; breathlessness, difficulty breathing when lying down, swelling of the feet or legs (signs of cardiac failure).</p><p>&bull; headache.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull; cough.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull; abdominal pain.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull; nausea.</p><p>&bull; diarrhoea.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull; tiredness.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull; weakness.</p><p>Not known:</p><p>&bull; rash, itching, together with some of the following signs or symptoms: fever, joint pain, muscle pain, swollen lymph nodes and/or flu-like symptoms (signs of serum sickness).</p><p>&bull; purple-red spots, fever, itching (signs of inflammation of blood vessels also called vasculitis).</p><p>&bull; unusual bleeding or bruising (signs of thrombocytopenia).</p><p>&bull; muscle pain (myalgia).</p><p>&bull; fever, sore throat or mouth ulcers due to infections (symptoms of low level of white blood cells also called neutropenia)</p><p>&bull; decrease of level of haemoglobin and decrease of the percentage of red blood cells in the blood (which can, in severe cases, lead to anaemia).</p><p>&bull; increase of level of potassium in the blood (which can, in severe cases, trigger muscle spasms, abnormal heart rhythm).</p><p>&bull; elevation of liver function values (which can indicate liver damage) including an increase of bilirubin in the blood (which can, in severe cases, trigger yellow skin and eyes).</p><p>&bull; increase of level of blood urea nitrogen and increase of level of serum creatinine (which can indicate abnormal kidney function).</p><p>&bull; low level of sodium in the blood (which can trigger tiredness, confusion, muscle twitching and/or convulsions in severe cases).</p><p>The frequency of some side effects may vary depending on your condition. For example, side effects such as dizziness, and decreased kidney function, were seen less frequently in patients treated with high blood pressure than in patients treated for heart failure or after a recent heart attack.</p><p>If any of the side effects gets serious or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep out of the reach and sight of children.</p><p>&bull; Do not use ARBITEN after the expiry date which is stated on the label and carton after EXP.</p><p>&bull; This medicinal product does not require any special storage conditions.</p><p>&bull; Do not use any ARBITEN pack that is damaged or shows signs of tampering.</p><p>&bull; Store below 30oC.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>ARBITEN 80 contains 80mg of Valsartan.</p><p>ARBITEN 160 contains 160mg of Valsartan.</p><p>The other ingredients are: Microcrystalline cellulose, Crospovidone, Talc, Colloidal silicone dioxide, Magnesium stearate, Sepifilm, Titanium dioxide &amp; Red iron oxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Pharmaceutical form: Film Coated Tablets.
Pack size: 30 Film Coated Tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Jordan Sweden Medical and Sterilization Company (Joswe-medical)</p><p>P.O. Box 851831 Amman 11185 Jordan</p><p>E-mail: joswe@go.com.jo</p><p>www.joswe.com</p><p>Tel: +962 6 5859765, +962 6 5728327</p><p>Fax: +962 6 5814526, +962 6 5728326</p><p>For any information about this medicinal product, please contact the local representative of the Marketing Authorization Holder:</p><p>Al-Dawaa Medical Services Co. Ltd.</p><p>P.O. Box 4326 Al Khobar 31952</p><p>www.al-dawaa.com</p><p>Tel: +966 13 845 0824</p><p>Fax: +966 13 859 5629</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised on 01/2020; Revision number R2.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">أربتين (فالسارتان) ينتمي إلى فئة من الأدوية تعرف باسم &quot;مضادات مستقبلات أنجيوتنسين II &quot;، والتي تساعد في السيطرة على ارتفاع ضغط الدم. أنجيوتنسين II هو عبارة عن مادة في الجسم تعمل على تحفيز انقباض الأوعية الدموية، مما يؤدي إلى ارتفاع ضغط الدم. يعمل فالسارتان عن طريق تثبيط أنجيوتنسين II، وهذا يؤدي إلى استرخاء الأوعية الدموية وانخفاض ضغط الدم.</p><p dir="RTL">تستعمل أقراص أربتين المغلفة غشائياً:&nbsp;</p><p dir="RTL">&bull; لعلاج المصابين حديثاً بأزمة قلبية (احتشاء عضلة القلب).&nbsp; حديثاً تعني هنا بين 12 ساعة و 10 أيام.</p><p dir="RTL">&bull; لعلاج مرضى قصور عضلة القلب. يستخدم أربتين عندما لا يمكن استخدام مجموعة من الأدوية تسمى مثبطات الإنزيم المحول للأنجيوتنسين (ACE) (دواء لعلاج قصور عضلة القلب).</p><p dir="RTL">وتشمل أعراض قصور عضلة&nbsp; القلب ضيق في التنفس وتورم في القدمين والساقين نتيجة لتراكم السوائل. يحدث ذلك عندما لا تتمكن عضلة القلب من ضخ الدم بقوة كافية لتزويد كل الدم اللازم لجميع أنحاء الجسم.</p><p dir="RTL">بالإضافة لذلك يمكن استخدام أربتين أقراص المغلفة غشائياً:</p><p dir="RTL">&bull; لعلاج ارتفاع ضغط الدم. ارتفاع ضغط الدم يزيد من الجهد على القلب والشرايين. إذا لم يتم علاجه فإنه يؤدي إلى تلف الأوعية الدموية في الدماغ والقلب والكلى، ويمكن أن يؤدي إلى سكتة دماغية وقصور عضلة القلب أو الكلى.</p><p dir="RTL">ارتفاع ضغط الدم يزيد من مخاطر التعرض لنوبات قلبية. العمل على تخفيض ضغط الدم لديك إلى المستويات الطبيعية يقلل من خطر الإصابة بهذه الاضطرابات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تتناول أربتين:</p><p dir="RTL">&bull; إذا كنت تعاني من الحساسية لفالسارتان أو لأي مكونات أخرى في هذا الدواء.</p><p dir="RTL">&bull; إذا كنت تعاني من مرض حاد في الكبد.</p><p dir="RTL">&bull; إذا كنت حامل لأكثر من ثلاثة أشهر (و يفضل أيضاً عدم تناول أربتين أقراص مغلفة غشائياً خلال المراحل الأولى من الحمل &ndash; راجع فقرة الحمل).</p><p dir="RTL">&bull; إذا كان لديك مرض السكري أو اختلال وظائف الكلى وتتعالج باستخدام&nbsp; دواء لخفض ضغط الدم يدعى أليسكيرين.</p><p dir="RTL">إذا كان أي مما ذكر أعلاه ينطبق عليك، لا تتناول هذا الدواء و قم باستشارة طبيبك.</p><p dir="RTL">التحذيرات و الاحتياطات:</p><p dir="RTL">&bull; اذا كنت تعاني من مرض في الكبد.</p><p dir="RTL">&bull; إذا كنت تعاني من مرض حاد في الكلى أو تتعالج بالغسيل الكلوي.</p><p dir="RTL">&bull; إذا كنت تعاني من تضيق شرايين الكلى.</p><p dir="RTL">&bull; إذا خضعت مؤخراً لزراعة الكلى.</p><p dir="RTL">&bull; إذا كنت تعاني من قصور في القلب أو تعرضت لنوبة قلبية. قد يتحقق طبيبك أيضاً من وظائف الكلى.</p><p dir="RTL">&bull; اذا كنت تعاني من مرض قلبي حاد غير قصور عضلة القلب أو نوبة قلبية.</p><p dir="RTL">&bull; إذا كنت تعاني في السابق من وذمة وعائية.</p><p dir="RTL">&bull; إذا كنت تتناول الأدوية الحافظة للبوتاسيوم، ومنها مكملات البوتاسيوم و بدائل الأملاح التي تحتوي على البوتاسيوم أو أي أدوية أخرى تعمل على زيادة كمية البوتاسيوم في الدم مثل الهيبارين. قد يحتاج طبيبك لفحص كمية البوتاسيوم في الدم بشكل منتظم.</p><p dir="RTL">&bull; إذا كنت تعاني من فرط إفراز الألدوستيرون، و هو عبارة عن مرض في الغدد الكظرية ينتج عنه إفراز كمية كبيرة من هرمون الألدوستيرون.&nbsp; إذا كان ذلك ينطبق عليك، لا يوصى باستعمال أربتين&nbsp; .</p><p dir="RTL">&bull;&nbsp; اذا كنت فقدت الكثير من السوائل (الجفاف) الناجم عن الإصابة بالإسهال أو القيء أو إذا كنت تتناول جرعات عالية من أقراص الماء (مدرات البول).</p><p dir="RTL">&bull; الأطفال و المراهقون: لا يوصى باستعمال أربتين للأطفال والمراهقين الأقل من 18 سنة.</p><p dir="RTL">&bull; الاستعمال المتزامن لمثبطات الأنزيم المحول للأنجيوتنسين (ACE) و مضادات مستقبلات الأنجيوتنسين (ARB) قد يؤدي إلى زيادة احتمالية حدوث ارتفاع مستوى البوتاسيوم و تراجع وظائف الكلى و هبوط الضغط. لذلك يجب عدم استعمالهما بشكل متزامن و خاصة المرضى الذين لديهم مشاكل في الكلى.</p><p dir="RTL">تناول أدوية أخرى:</p><p dir="RTL">يرجى إخبار الطبيب أو الصيدلي إذا كنت تتناول أو تناولت مؤخرا أي أدوية أخرى، بما في ذلك الأدوية التي تم تناولها بدون وصفة طبية.</p><p dir="RTL">قد يتأثر العلاج إذا تم تناول أربتين بشكل متزامن مع بعض الأدوية الأخرى. قد يكون من الضروري تغيير الجرعة واتخاذ احتياطات أخرى أو في بعض الحالات إلى التوقف عن تناول أحد الأدوية. ينطبق ذلك خصوصاً على الأدوية التالية:</p><p dir="RTL">&bull; الأدوية الأخرى التي تخفض ضغط الدم و خاصة أقراص الماء (مدرات البول).</p><p dir="RTL">&bull; الأدوية أو المواد التي قد تزيد من كمية البوتاسيوم في الدم. وتشمل مكملات البوتاسيوم أو بدائل الأملاح التي تحتوي على البوتاسيوم والأدوية الحافظة للبوتاسيوم و الهيبارين.</p><p dir="RTL">&bull; مسكنات الألم مثل الأدوية غير الستيرويدية المضادة للالتهابات.</p><p dir="RTL">&bull; بعض المضادات الحيوية (مجموعة ريفاميسن)، وهو دواء يستخدم لحماية ضد رفض الزرع (سيكلوسبورين) أو دواء المضاد للفيروسات المستخدمة لعلاج العدوى بفيروس نقص المناعة البشرية / الإيدز (ريتونافير). هذه الأدوية قد تزيد من تأثير أربتين .</p><p dir="RTL">&bull; الليثيوم، وهو دواء يستخدم لعلاج أنواع معينة من الأمراض النفسية.</p><p dir="RTL">&bull; الأدوية الأخرى المستخدمة لخفض ضغط الدم بما في ذلك ميثيل دوبا، مدرات البول (أقراص الماء)، مثبطات ACE (مثل إنالابريل، ليزينوبريل،...) أو أليسكيرين.</p><p dir="RTL">تناول أربتين مع الطعام:</p><p dir="RTL">يمكنك أن تتناول أربتين مع أو بدون الطعام.</p><p dir="RTL">الحمل والإرضاع:</p><p dir="RTL">إسأل طبيبك أو الصيدلي للحصول على المشورة قبل تناول أي دواء.</p><p dir="RTL">&bull; اسألي طبيبك إذا كنت حاملا أو&nbsp; تخططين للإنجاب، بالعادة سينصحك بالتوقف عن تناول أربتين&nbsp; قبل أن تصبحي حامل أو في حال علمك بأنك حامل، وسيقوم باستبدال أربتين بدواء آخر. لا يوصى بتناول أربتين خلال المرحلة الأولى من الحمل، ويجب عدم تناوله بعد الشهر الثالث من الحمل، لأنه قد يسبب ضرر جسيم لطفلك إذا تم استخدامه بعد الشهر الثالث من الحمل.</p><p dir="RTL">&bull; أخبري طبيبك إذا كنت مرضعة أو على وشك البدء بالإرضاع. لا يوصى بتناول أربتين للأمهات المرضعات، وقد يختار الطبيب علاج آخر بالنسبة لك إذا كنت ترغبين بالإرضاع، وخصوصاً&nbsp; إذا كان طفلك حديث الولادة أو خديج.</p><p dir="RTL">القيادة وتشغيل الآلات:</p><p dir="RTL">يجب التأكد من كيفية تفاعلك مع أربتين قبل قيادة المركبات أو استخدام الأدوات أو تشغيل الآلات أو القيام بأي أنشطة أخرى تتطلب التركيز. كما هو الحال مع العديد من الأدوية التي تستخدم لعلاج ارتفاع ضغط الدم، في حالات نادرة&nbsp; قد يسبب أربتين الدوخة و يؤثر على القدرة على التركيز.</p><p dir="RTL">معلومات هامة عن بعض مكونات أربتين:&nbsp;</p><p dir="RTL">لا يوجد.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">دائماً تناول دوائك كما أخبرك الطبيب أو الصيدلاني. سيساعد ذلك في الحصول على أفضل النتائج و تقليل خطورة الآثار الجانبية.&nbsp; إذا لم تكن متأكداً،&nbsp; قم باستشارة طبيبك أو الصيدلاني. غالباً الأشخاص المصابون بارتفاع ضغط الدم لا يلاحظون أي علامة لظهور هذه المشكلة. معظمهم قد يشعرون بالوضع الطبيعي لهم. هذا يجعل الأمر أكثر أهمية بالنسبة لك للحفاظ على مواعيدك مع الطبيب حتى لو كنت على ما يرام.</p><p dir="RTL">&bull; المصابين حديثا بأزمة قلبية: يبدأ العلاج في وقت مبكر بعد الاصابة بأزمة قلبية عموما بعد 12 ساعة، وعادة بجرعة منخفضة من 20 ملجم مرتين يومياً. سوف يزيد طبيبك هذه الجرعة تدريجيا على مدى عدة أسابيع بحد أقصى 160 ملجم مرتين يومياً. الجرعة النهائية تعتمد على قدرتك كمريض للتحمل.</p><p dir="RTL">يمكن إعطاء أربتين بالتزامن مع غيره من الأدوية لعلاج الأزمة القلبية، والطبيب سوف يقرر أي علاج هو مناسب لك.</p><p dir="RTL">&bull; قصورعضلة&nbsp; القلب: يبدأ العلاج بشكل عام مع 40 ملجم مرتين يومياً. سوف يزيد طبيبك هذه الجرعة تدريجياً على مدى عدة أسابيع بحد أقصى 160 ملجم مرتين يومياً. الجرعة النهائية تعتمد على قدرتك كمريض للتحمل.</p><p dir="RTL">يمكن إعطاء أربتين بالتزامن مع غيره من الأدوية لعلاج قصورعضلة&nbsp; القلب، والطبيب سوف يقرر أي علاج هو مناسب لك.</p><p dir="RTL">&bull; ارتفاع ضغط الدم: الجرعة المعتادة هي 80 ملجم يومياً. في بعض الحالات قد يصف الطبيب جرعات أعلى (على سبيل المثال 160 ملجم أو 320 ملجم). وقد يقوم بوصف أربتين مع دواء إضافي (مثل مدر للبول).</p><p dir="RTL">&bull; يمكن تناول أقراص أربتين مع أو دون تناول الطعام. تناول القرص مع كوب من الماء.</p><p dir="RTL">&bull; يجب تناول هذا الدواء في نفس الوقت من كل يوم.</p><p dir="RTL">إذا تناولت أقراص أربتين أكثر مما يجب:</p><p dir="RTL">إذا شعرت بدوار حاد و/أو إغماء، استلقي و قم بالاتصال بطبيبك فوراً.&nbsp; إذا تناولت بالخطأ أكثر مما يجب، قم بالاتصال بطبيبك أو الصيدلاني أو المستشفى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا نسيت تناول جرعة أربتين:&nbsp;</p><p dir="RTL">إذا نسيت تناول الجرعة تناولها حال تذكرك لها، عموماً، لا تتناول الجرعة التي نسيتها إذا اقترب موعد الجرعة التالية. لا تتناول جرعة مضاعفة لتعويض الجرعة التي نسيتها.</p><p dir="RTL">إذا توقفت عن تناول أربتين:&nbsp;</p><p dir="RTL">قد يسبب التوقف عن تناول العلاج أربتين ازدياد سوء ارتفاع ضغط الدم.&nbsp; لا تتوقف عن تناول دوائك ما لم يطلب منك الطبيب ذلك.</p><p dir="RTL">إذا كان لديك أي أسئلة اضافية عن استعمال هذا الدواء، قم باستشارة الطبيب أو الصيدلاني.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كل الأدوية، قد يسبب أربتين آثار جانبية على الرغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">قد تحدث هذه الآثار الجانبية بتكرارات مختلفة، والتي تعرف كما يلي:</p><p dir="RTL">&bull;&nbsp; شائعة جداً: تؤثر على أكثر من 1 من كل&nbsp; 10 مستخدمين.</p><p dir="RTL">&bull; شائعة : تؤثر على 1 إلى 10 من كل 100 مستخدم.</p><p dir="RTL">&bull; غير شائعة: تؤثر على 1 إلى 10 من كل 1000 مستخدم.</p><p dir="RTL">&bull; نادرة: تؤثر على 1 إلى 10 من كل 10000 مستخدم.</p><p dir="RTL">&bull; نادرة جداً: تؤثر على أقل من 1&nbsp; من كل 10000 مستخدم.</p><p dir="RTL">&bull; غير معروفة: لا يمكن تقدير تكرار حدوثها من المعلومات المتوفرة.</p><p dir="RTL">بعض الآثار الجانبية تحتاج إلى عناية طبية فورية:</p><p dir="RTL">يجب مراجعة الطبيب فورا إذا حدثت لك&nbsp; أعراض وذمة وعائية، مثل :</p><p dir="RTL">&bull; تورم الوجه واللسان أو البلعوم.</p><p dir="RTL">&bull; صعوبة في البلع.</p><p dir="RTL">&bull; شرى و صعوبات في التنفس.</p><p dir="RTL">اذا كان لديك أي من هذه الأعراض، توقف عن تناول أربتين واتصل بطبيبك على الفور (راجع أيضا فقرة (التحذيرات و الاحتياطات).</p><p dir="RTL">الآثار الجانبية الأخرى:</p><p dir="RTL">شائعة:</p><p dir="RTL">&bull; الدوخة و الدوخة عند الوقوف.</p><p dir="RTL">&bull; انخفاض ضغط الدم مع أو بدون أعراض مثل الدوخة أو الإغماء عند الوقوف.</p><p dir="RTL">&bull; انخفاض وظائف الكلى (علامات للفشل الكلوي).</p><p dir="RTL">غير شائعة:</p><p dir="RTL">&bull; رد فعل تحسسي مع أعراض مثل الطفح الجلدي&nbsp; والحكة&nbsp; والدوخة&nbsp; و تورم في الوجه أو الشفتين أو اللسان أو الحلق&nbsp; وصعوبة في التنفس أو البلع (علامات على وذمة وعائية).</p><p dir="RTL">&bull; فقدان مفاجئ للوعي.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull; الإحساس بالدوران.</p><p dir="RTL">&bull; انخفاض شديد في وظائف الكلى (علامات الفشل الكلوي الحاد).&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull; تشنجات العضلات&nbsp; وضربات القلب غير طبيعية (علامات ارتفاع مستوى البوتاسيوم).</p><p dir="RTL">&bull; ضيق في التنفس و صعوبة في التنفس عند الاستلقاء&nbsp; و تورم في الساقين أو القدمين (علامات قصور عضلة القلب).</p><p dir="RTL">&bull; الصداع.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull; السعال.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull; ألم في البطن.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull; الغثيان.</p><p dir="RTL">&bull; الإسهال.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull; التعب.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull; ضعف.</p><p dir="RTL">غير معروفة:</p><p dir="RTL">&bull; الطفح الجلدي&nbsp; والحكة&nbsp; بالتزامن مع بعض من العلامات التالية: ارتفاع درجة الحرارة وآلام المفاصل و آلام في العضلات وتضخم الغدد الليمفاوية و/ أو أعراض تشبه الانفلونزا.</p><p dir="RTL">&bull; البقع الأرجواني- الحمراء والحمى والحكة (علامات التهاب الأوعية الدموية).</p><p dir="RTL">&bull; نزيف غير عادي أو كدمات (علامات نقص الصفيحات).</p><p dir="RTL">&bull; ألم في العضلات.</p><p dir="RTL">&bull; الحمى&nbsp; والتهاب الحلق أو تقرحات في الفم بسبب الالتهابات (أعراض انخفاض مستوى خلايا الدم البيضاء وتسمى أيضا العدلات).</p><p dir="RTL">&bull; انخفاض مستوى الهيموجلوبين وانخفاض نسبة خلايا الدم الحمراء في الدم (والتي يمكن، في الحالات الشديدة،أن تؤدي إلى فقر الدم).</p><p dir="RTL">&bull; زيادة مستوى البوتاسيوم في الدم (والتي يمكن، في الحالات الشديدة، أن تسبب تشنج العضلات و إيقاع غير طبيعي للقلب).</p><p dir="RTL">&bull; ارتفاع قيم وظائف الكبد (والتي يمكن أن تشير إلى تلف الكبد) بما في ذلك زيادة البيليروبين في الدم (والتي يمكن في الحالات الشديدة، أن يؤدي الى اصفرار البشرة والعيون).</p><p dir="RTL">&bull; ارتفاع مستوى نيتروجين اليوريا والكرياتينين في الدم (والذي قد يشير إلى اضطراب في وظيفة الكلى).</p><p dir="RTL">&bull; انخفاض مستوى الصوديوم في الدم (والذي يمكن أن يؤدي إلى التعب والارتباك، وارتعاش العضلات و/أو تشنجات في الحالات الشديدة).</p><p dir="RTL">تكرار حدوث بعض الآثار الجانبية قد يختلف تبعاً لحالتك. على سبيل المثال، الآثار الجانبية مثل الدوخة&nbsp; وانخفاض وظائف الكلى&nbsp; حدثت بنسبة&nbsp; أقل كثيراً في مرضى ارتفاع ضغط الدم مقارنة بمرضى قصور عضلة القلب أو المرضى المصابين بأزمة قلبية حديثة.</p><p dir="RTL">يرجى إخبار الطبيب أو الصيدلي في حال أصبحت أي من الآثار الجانبية خطيرة، أو إذا لاحظت أي آثار جانبية غير مذكورة في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull; يحفظ بعيدا عن متناول الأطفال.</p><p dir="RTL">&bull; لا تستخدم أربتين&nbsp; بعد انتهاء فترة الصلاحية&nbsp; المذكورة على اللاصق الداخلي و العبوة الخارجية.</p><p dir="RTL">&bull; لا يتطلب هذا المنتج الدوائي أي ظروف تخزين خاصة.</p><p dir="RTL">&bull; لا تستخدم أربتين عند ملاحظة أي علامة تلف فيه.</p><p dir="RTL">&bull; يخزن في درجة حرارة أقل من 30 درجة مئوية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull; أربتين 80&nbsp; يحتوي على 80 ملجم فالسارتان.</p><p dir="RTL">&bull; أربتين 160&nbsp; يحتوي على ١٦0 ملجم فالسارتان.</p><p>المكونات الأخرى هي: مايكروكريستالين سليلوز، كروس بوفيدون، تالك، كولويدال سيليكون دايوكسيد، مغنيسيوم ستيرات، سيبيفيلم، تيتانيوم دايوكسيد و أكسيد الحديد الأحمر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الشكل الصيدلاني: أقراص مغلفة غشائياً.</p><p dir="RTL">حجم العبوة: 30 قرص مغلفة غشائياً.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الشركة الأردنية السويدية للمنتجات الطبية و التعقيم.</p><p dir="RTL">صندوق بريد 851831&nbsp; عمان 11185&nbsp; الأردن</p><p dir="RTL">الايميل: joswe@go.com.jo</p><p dir="RTL">www.joswe.com</p><p dir="RTL">هاتف:&nbsp;&nbsp;&nbsp; +962 6 5859765 ، +962 6 5728327</p><p dir="RTL">فاكس: +962 6 5814526، +962 6&nbsp; 5728326</p><p dir="RTL">للحصول على أي معلومات عن هذا المنتج الدوائي، يرجى الاتصال بالوكيل المحلي للشركة المالكة لحق التسويق:</p><p dir="RTL">شركة الدواء للخدمات الطبية المحدودة</p><p dir="RTL">صندوق بريد 4326 الخبر 31952</p><p dir="RTL">www.al-dawaa.com</p><p dir="RTL">هاتف:&nbsp;&nbsp;&nbsp; +966 13 845 08234</p><p dir="RTL">فاكس: +966 13 859 5629</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة في 01/2020  ؛ رقم المراجعة R2 .
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Arbiten® 80mg Film Coated Tablet 
Arbiten® 160 mg Film Coated Tablet
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Arbiten® 80mg Film Coated Tablet : One film coated tablet contains 80mg of valsartan 
Arbiten® 160mg Film Coated Tablet : One film coated tablet contains 160mg of valsartan
For a full list of excipients, see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film Coated Tablet.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hypertension<br />Treatment of essential hypertension in adults.<br />Recent myocardial infarction<br />Treatment of clinically stable adult patients with symptomatic heart failure or asymptomatic left ventricular systolic dysfunction after a recent (12 hours-10 days) myocardial infarction (see sections 4.4 and 5.1)<br />Heart failure<br />Treatment of adult patients with symptomatic heart failure when ACE-inhibitors are not tolerated or in beta-blocker intolerant patients as add-on therapy to ACE inhibitors when mineralocorticoid receptor antagonists cannot be used (see sections 4.2, 4.4, 4.5 and 5.1)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />Recent myocardial infarction<br />In clinically stable patients, therapy may be initiated as early as 12 hours after a myocardial infarction. After an initial dose of 20 mg valsartan twice daily, valsartan should be titrated to 40 mg, 80 mg, and 160 mg twice daily over the next few weeks.<br />The starting dose is provided by a 40 mg divisible film coated tablet, obtained from a different source.</p><p>The target maximum dose is 160 mg twice daily. In general, it is recommended that patients achieve a dose level of 80 mg twice daily by two weeks after treatment initiation and that the target maximum dose, 160 mg twice daily, be achieved by three months, based on the patient&#39;s tolerability. If symptomatic hypotension or renal dysfunction occur, consideration should be given to a dosage reduction.<br />Valsartan may be used in patients treated with other post-myocardial infarction therapies, e.g. thrombolytics, acetylsalicylic acid, beta blockers, statins, and diuretics. The combination with ACE inhibitors is not recommended (see sections 4.4 and 5.1).<br />Evaluation of post-myocardial infarction patients should always include assessment of renal function.<br />Heart failure<br />The recommended starting dose of Valsartan Tablets is 40mg twice daily. Uptitration to 80mg and 160mg twice daily should be done at intervals of at least two weeks to the highest dose, as tolerated by the patient. Consideration should be given to reducing the dose of concomitant diuretics. The maximum daily dose administered in clinical trials is 320 mg in divided doses.<br />Valsartan may be administered with other heart failure therapies. However, the triple combination of an ACE-inhibitor, valsartan and a beta blocker or a potassium-sparing diuretic is not recommended (see sections 4.4 and 5.1).<br />Evaluation of patients with heart failure should always include assessment of renal function.<br />Hypertension<br />The recommended starting dose of Valsartan Film Coated Tablet is 80mg once daily.<br />The antihypertensive effect is substantially present within 2 weeks, and maximal effects are attained within 4 weeks. In some patients whose blood pressure is not adequately controlled, the dose can be increased to 160mg and to a maximum of 320mg.<br />Valsartan Film Coated Tablet may also be administered with other antihypertensive agents. The addition of a diuretic such as hydrochlorothiazide will decrease blood pressure even further in these patients.<br />Additional information on special populations<br />Elderly<br />No dose adjustment is required in elderly patients.<br />Renal impairment<br />No dose adjustment is required for patients with a creatinine clearance &gt; 10 ml/min (see sections 4.4 and 5.2) . Concomitant use of Valsartan Film Coated Tablets with aliskiren is contraindicated in patients with renal impairment (GFR &lt; 60 mL/min/1.73 m<sup>2</sup>) (see section 4.3).<br />Diabetes Mellitus<br />Concomitant use of Valsartan Film Coated Tablets with aliskiren is contraindicated in patients with diabetes mellitus (see section 4.3).<br />Hepatic impairment<br />Valsartan Film Coated Tablets are contraindicated in patients with severe hepatic impairment, biliary cirrhosis and in patients with cholestasis (see sections 4.3, 4.4 and 5.2). In patients with mild to moderate hepatic impairment without cholestasis, the dose of valsartan should not exceed 80mg.</p><p>Paediatric population<br />Paediatric hypertension<br />Children and adolescents 6 to 18 years of age<br />The initial dose is 40 mg once daily for children weighing below 35 kg and 80 mg once daily for those weighing 35 kg or more. The dose should be adjusted based on blood pressure response. For maximum doses studied in clinical trials please refer to the table below.<br />Doses higher than those listed have not been studied and are therefore not recommended.<br />Weight&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Maximum dose studied in clinical trials<br />&ge;18 kg to &lt;35 kg&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;80 mg<br />&ge;35 kg to &lt;80 kg&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 160 mg<br />&ge;80 kg to &le;160 kg&nbsp; &nbsp; &nbsp; &nbsp; 320 mg<br />Children less than 6 years of age<br />Available data are described in sections 4.8, 5.1 and 5.2. However safety and efficacy of valsartan in children aged 1 to 6 years have not been established.<br />Use in paediatric patients aged 6 to 18 years with renal impairment<br />Use in paediatric patients with a creatinine clearance &lt;30 ml/min and paediatric patients undergoing dialysis has not been studied, therefore valsartan is not recommended in these patients. No dose adjustment is required for paediatric patients with a creatinine clearance &gt;30 ml/min. Renal function and serum potassium should be closely monitored (see sections 4.4 and 5.2).<br />Use in paediatric patients aged 6 to 18 years with hepatic impairment<br />As in adults, valsartan is contraindicated in paediatric patients with severe hepatic impairment, biliary cirrhosis and in patients with cholestasis (see sections 4.3, 4.4 and 5.2). There is limited clinical experience with valsartan in paediatric patients with mild to moderate hepatic impairment. The dose of valsartan should not exceed 80 mg in these patients.<br />Paediatric heart failure and recent myocardial infarction<br />Valsartan is not recommended for the treatment of heart failure or recent myocardial infarction in children and adolescents below the age of 18 years due to the lack of data on safety and efficacy.<br />Method of administration<br />Valsartan Film Coated Tablets may be taken independently of a meal and should be administered with water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                - Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
- Severe hepatic impairment, biliary cirrhosis and cholestasis.
- Second and third trimester of pregnancy (see sections 4.4 and 4.6).
- The concomitant use of Valsartan with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td>WARNING: FETAL TOXICITY<br /> When pregnancy is detected, discontinue Valsartan as soon as possible.<br /> Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.</td></tr></tbody></table><p>Hyperkalaemia<br />Concomitant use with potassium supplements, potassium-sparing diuretics, salt substitutes containing potassium, or other agents that may increase potassium levels (heparin, etc.) is not recommended. Monitoring of potassium should be undertaken as appropriate.<br />Impaired renal function<br />There is currently no experience on the safe use in patients with a creatinine clearance &lt;10 ml/min and patients undergoing dialysis, therefore valsartan should be used with caution in these patients. No dose adjustment is required for adult patients with creatinine clearance &gt;10 ml/min (see sections 4.2 and 5.2). The concomitant use of AIIRAs, including valsartan, or of ACE inhibitors with aliskiren is contraindicated in patients with renal impairment (GFR &lt; 60 mL/min/1.73 m<sup>2</sup>) (see sections 4.3 and 4.5).<br />Hepatic impairment<br />In patients with mild to moderate hepatic impairment without cholestasis, valsartan should be used with caution (see sections 4.2 and 5.2).<br />Sodium- and/or volume-depleted patients<br />In severely sodium-depleted and/or volume-depleted patients, such as those receiving high doses of diuretics, symptomatic hypotension may occur in rare cases after initiation of therapy with valsartan. Sodium and/or volume depletion should be corrected before starting treatment with valsartan, for example by reducing the diuretic dose.<br />Renal artery stenosis<br />In patients with bilateral renal artery stenosis or stenosis to a solitary kidney, the safe use of valsartan has not been established.<br />Short-term administration of valsartan to twelve patients with renovascular hypertension secondary to unilateral renal artery stenosis did not induce any significant changes in renal haemodynamics, serum creatinine, or blood urea nitrogen (BUN). However, other agents that affect the renin-angiotensin system may increase blood urea and serum creatinine in patients with unilateral renal artery stenosis, therefore monitoring of renal function is recommended when patients are treated with valsartan.<br />Kidney transplantation<br />There is currently no experience on the safe use of valsartan in patients who have recently undergone kidney transplantation.<br />Primary hyperaldosteronism<br />Patients with primary hyperaldosteronism should not be treated with valsartan as their renin-angiotensin system is not activated.<br />Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy<br />As with all other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or hypertrophic obstructive cardiomyopathy (HOCM).<br />Pregnancy<br />Angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy. Unless continued AIIRAs therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped&nbsp;immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).<br />Recent myocardial infarction<br />The combination of captopril and valsartan has shown no additional clinical benefit, instead the risk for adverse events increased compared to treatment with the respective therapies (see sections 4.2 and 5.1). Therefore, the combination of valsartan with an ACE inhibitor is not recommended.<br />Caution should be observed when initiating therapy in post-myocardial infarction patients. Evaluation of post-myocardial infarction patients should always include assessment of renal function (see section 4.2).<br />Use of valsartan in post-myocardial infarction patients commonly results in some reduction in blood pressure, but discontinuation of therapy because of continuing symptomatic hypotension is not usually necessary provided dosing instructions are followed (see section 4.2).<br />Heart Failure</p><p>The risk of adverse reactions, especially hypotension, hyperkalaemia and decreased renal function (including acute renal failure), may increase when Valsartan is used in combination with an ACE-inhibitor. In patients with heart failure, the triple combination of an ACE inhibitor, a beta blocker and valsartan has not shown any clinical benefit (see section 5.1). This combination apparently increases the risk for adverse events and is therefore not recommended. Triple combination of an ACE-inhibitor, a mineralocorticoid receptor antagonist and valsartan is also not recommended. Use of these combinations should be under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.</p><p>Caution should be observed when initiating therapy in patients with heart failure. Evaluation of patients with heart failure should always include assessment of renal function (see section 4.2).<br />Use of valsartan in patients with heart failure commonly results in some reduction in blood pressure, but discontinuation of therapy because of continuing symptomatic hypotension is not usually necessary provided dosing instructions are followed (see section 4.2).<br />In patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone-system (e.g patients with severe congestive heart failure), treatment with ACE-inhibitors has been associated with oliguria and/or progressive azotaemia and in rare cases with acute renal failure and/or death. As valsartan is an angiotensin II receptor blocker, it cannot be excluded that the use of valsartan may be associated with impairment of the renal function.<br />ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.</p><p>History of angioedema<br />Angioedema, including swelling of the larynx and glottis, causing airway obstruction and/or swelling of the face, lips, pharynx, and/or tongue has been reported in patients treated with valsartan; some of these patients previously experienced angioedema with other drugs including ACE inhibitors. Valsartan should be immediately discontinued in patients who develop angioedema, and valsartan should not be re-administered.<br />Dual Blockade of the Renin-Angiotensin-Aldosterone System (RAAS)</p><p>There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended (see sections 4.5 and 5.1).<br />If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.<br />ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.<br />Paediatric population<br />Impaired renal function</p><p>Use in paediatric patients with a creatinine clearance &lt;30 ml/min and paediatric patients undergoing dialysis has not been studied, therefore valsartan is not recommended in these patients. No dose adjustment is required for paediatric patients with a creatinine clearance &gt;30 ml/min (see sections 4.2 and 5.2). Renal function and serum potassium should be closely monitored during treatment with valsartan. This applies particularly when valsartan is given in the presence of other conditions (fever, dehydration) likely to impair renal function. The concomitant use of AIIRAs, including valsartan, or of ACE inhibitors with aliskiren is contraindicated in patients with renal impairment (GFR &lt; 60 mL/min/1.73m<sup>2</sup>) (see sections 4.3 and 4.5).<br />Impaired hepatic function<br />As in adults, valsartan is contraindicated in paediatric patients with severe hepatic impairment, biliary cirrhosis and in patients with cholestasis (see sections 4.3 and 5.2). There is limited clinical experience with valsartan in paediatric patients with mild to moderate hepatic impairment. The dose of valsartan should not exceed 80 mg in these patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dual blockage of the Renin-Angiotensin-System (RAS) with AIIRAs, ACE inhibitors, or aliskiren:<br />Clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone-system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).<br />Concomitant use not recommended<br />Lithium<br />Reversible increases in serum lithium concentrations and toxicity have been reported during concurrent use of ACE inhibitors. Due to the lack of experience with concomitant use of valsartan and lithium, this combination is not recommended. If the combination proves necessary, careful monitoring of serum lithium levels is recommended.<br />Potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium and other substances that may increase potassium levels</p><p>If a medicinal product that affects potassium levels is considered necessary in combination with valsartan, monitoring of potassium plasma levels is advised.</p><p>Caution required with concomitant use<br />Non-steroidal anti-inflammatory medicines (NSAIDs), including selective COX-2 inhibitors, acetylsalicylic acid &gt;3 g/day), and non-selective NSAIDs<br />When angiotensin II antagonists are administered simultaneously with NSAIDs, attenuation of the antihypertensive effect may occur. Furthermore, concomitant use of angiotensin II antagonists and NSAIDs may lead to an increased risk of worsening of renal function and an increase in serum potassium. Therefore, monitoring of renal function at the beginning of the treatment is recommended, as well as adequate hydration of the patient.<br />Others<br />In drug interaction studies with valsartan, no interactions of clinical significance have been found with valsartan or any of the following substances: cimetidine, warfarin, furosemide, digoxin, atenolol, indometacin, hydrochlorothiazide, amlodipine, glibenclamide.<br />Paediatric population<br />In hypertension in children and adolescents, where underlying renal abnormalities are common, caution is recommended with the concomitant use of valsartan and other substances that inhibit the renin angiotensin<br />aldosterone system which may increase serum potassium. Renal function and serum potassium should be closely monitored.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td>The use of Angiotensin II Receptor Antagonists (AIIRAs) is not recommended during the first trimester of pregnancy (see section 4.4). The use of AIIRAs is contra-indicated during the second and third trimester of pregnancy (see sections 4.3 and 4.4).</td></tr></tbody></table><p>Pregnancy Category D.<br />Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however, a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with AIIRAs, similar risks may exist for this class of drugs. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started.<br />AIIRAs therapy exposure during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalemia); see also section 5.3 &ldquo;Preclinical safety data&rdquo;.<br />Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.<br />Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see also sections 4.3 and 4.4).</p><p>Breastfeeding<br />Because no information is available regarding the use of valsartan during breastfeeding, valsartan is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.<br />Fertility<br />Valsartan had no adverse effects on the reproductive performance of male or female rats at oral doses up to 200mg/kg/day. This dose is 6 times the maximum recommended human dose on a mg/m2 basis (calculations assume an oral dose of 320mg/day and a 60kg patient).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive have been performed. When driving vehicles or operating machines it should be taken into account that occasionally dizziness or weariness may occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In controlled clinical studies in patients with hypertension, the overall incidence of adverse reactions (ADRs) was comparable with placebo and is consistent with the pharmacology of valsartan. The incidence of ADRs did not appear to be related to dose or treatment duration and also showed no association with gender, age or race.<br />The ADRs reported from clinical studies, post-marketing experience and laboratory findings are listed below according to system organ class.<br />Adverse reactions are ranked by frequency, the most frequent first, using the following convention:<br />&bull; Very common (&ge; 1/10)<br />&bull; Common (&ge; 1/100 to &lt; 1/10)<br />&bull; Uncommon (&ge; 1/1,000 to &lt; 1/100)<br />&bull; Rare (&ge; 1/10,000 to &lt; 1/1,000)<br />&bull; Very rare (&lt; 1/10,000), including isolated reports<br />Within each frequency grouping, adverse reactions are ranked in order of decreasing seriousness.<br />For all the ADRs reported from post-marketing experience and laboratory findings, it is not possible to apply any ADR frequency and therefore they are mentioned with a &quot;not known&quot; frequency.<br />&bull;Hypertension</p><table border="1" cellspacing="1" cellpadding="1" style="width:666px"><tbody><tr><td colspan="2" style="width:663px">Blood and lymphatic system disorders</td></tr><tr><td style="width:293px">Not known</td><td style="width:368px">Decrease in haemoglobin, Decrease in haematocrit, Neutropenia, Thrombocytopenia</td></tr><tr><td colspan="2" style="width:663px">Immune system disorders</td></tr><tr><td style="width:293px">Not known</td><td style="width:368px">Hypersensitivity including serum sickness</td></tr><tr><td colspan="2" style="width:663px">Metabolism and nutrition disorders</td></tr><tr><td style="width:293px">Not known</td><td style="width:368px">Increase of serum potassium, Hyponatraemia</td></tr><tr><td colspan="2" style="width:663px">Ear and labyrinth disorders</td></tr><tr><td style="width:293px">Uncommon</td><td style="width:368px">Vertigo</td></tr><tr><td colspan="2" style="width:663px">Vascular disorders</td></tr><tr><td style="width:293px">Not known</td><td style="width:368px">Vasculitis</td></tr><tr><td colspan="2" style="width:663px">Respiratory, thoracic and mediastinal disorders</td></tr><tr><td style="width:293px">Uncommon</td><td style="width:368px">Cough</td></tr><tr><td colspan="2" style="width:663px">Gastrointestinal disorders</td></tr><tr><td style="width:293px">Uncommon</td><td style="width:368px">Abdominal pain</td></tr><tr><td colspan="2" style="width:663px">Hepato-biliary disorders</td></tr><tr><td style="width:293px">Not known</td><td style="width:368px">Elevation of liver function values including increase of serum bilirubin</td></tr><tr><td colspan="2" style="width:663px">Skin and subcutaneous tissue disorders</td></tr><tr><td style="width:293px">Not known</td><td style="width:368px">Angioedema, Rash, Pruritus</td></tr><tr><td colspan="2" style="width:663px">Musculoskeletal and connective tissue disorders</td></tr><tr><td style="width:293px">Not known</td><td style="width:368px">Myalgia</td></tr><tr><td style="width:293px">Renal and urinary disorders</td><td style="width:368px">&nbsp;</td></tr><tr><td style="width:293px">Not known</td><td style="width:368px">Renal failure and impairment, Elevation of serum creatinine</td></tr><tr><td colspan="2" style="width:293px">General disorders and administration site conditions</td></tr><tr><td style="width:293px">Uncommon</td><td style="width:368px">Fatigue</td></tr></tbody></table><p>Paediatric population<br />Hypertension</p><p>The antihypertensive effect of valsartan has been evaluated in two randomised, double-blind clinical studies in 561 paediatric patients from 6 to 18 years of age. With the exception of isolated gastrointestinal disorders<br />(like abdominal pain, nausea, vomiting) and dizziness, no relevant differences in terms of type, frequency and severity of adverse reactions were identified between the safety profile for paediatric patients aged 6 to 18 years and that previously reported for adult patients.<br />Neurocognitive and developmental assessment of paediatric patients aged 6 to 16 years of age revealed no overall clinically relevant adverse impact after treatment with valsartan for up to one year.<br />In a double-blind randomized study in 90 children aged 1 to 6 years, which was followed by a one-year open-label extension, two deaths and isolated cases of marked liver transaminases elevations were observed. These cases occurred in a population who had significant comorbidities. A causal relationship to valsartan has not been established. In a second study in which 75 children aged 1 to 6 years were randomised, no significant liver transaminase elevations or death occurred with valsartan treatment.<br />Hyperkalaemia was more frequently observed in children and adolescents aged 6 to 18 years with underlying chronic kidney disease.</p><p>The safety profile seen in controlled-clinical studies in patients with post-myocardial infarction and/or heart failure varies from the overall safety profile seen in hypertensive patients. This may relate to the patients underlying disease. ADRs that occurred in post-myocardial infarction and/or heart failure patients are listed below:<br />&bull;Post-myocardial infarction and/or heart failure (studied in adult patients only)</p><table border="1" cellspacing="1" cellpadding="1" style="width:576px"><tbody><tr><td colspan="2" style="width:573px">Blood and lymphatic system disorders</td></tr><tr><td style="width:294px">Not known</td><td style="width:278px">Thrombocytopenia</td></tr><tr><td colspan="2" style="width:573px">Immune system disorders</td></tr><tr><td style="width:294px">Not known</td><td style="width:278px">Hypersensitivity including serum sickness</td></tr><tr><td style="width:294px">Metabolism and nutrition disorders</td><td style="width:278px">&nbsp;</td></tr><tr><td style="width:294px">Uncommon</td><td style="width:278px">Hyperkalaemia</td></tr><tr><td style="width:294px">Not known</td><td style="width:278px">Increase of serum potassium, Hyponatraemia</td></tr><tr><td style="width:294px">Nervous system disorders</td><td style="width:278px">&nbsp;</td></tr><tr><td style="width:294px">Common</td><td style="width:278px">Dizziness, Postural dizziness</td></tr><tr><td style="width:294px">Uncommon</td><td style="width:278px">Syncope, Headache</td></tr><tr><td style="width:294px">Ear and labyrinth disorders</td><td style="width:278px">&nbsp;</td></tr><tr><td style="width:294px">Uncommon</td><td style="width:278px">Vertigo</td></tr><tr><td style="width:294px">Cardiac disorders</td><td style="width:278px">&nbsp;</td></tr><tr><td style="width:294px">Uncommon</td><td style="width:278px">Cardiac failure</td></tr><tr><td style="width:294px">Vascular disorders</td><td style="width:278px">&nbsp;</td></tr><tr><td style="width:294px">Common</td><td style="width:278px">Hypotension, Orthostatic hypotension</td></tr><tr><td style="width:294px">Not known</td><td style="width:278px">Vasculitis</td></tr><tr><td style="width:294px">Respiratory, thoracic and mediastinal disorders</td><td style="width:278px">&nbsp;</td></tr><tr><td style="width:294px">Uncommon</td><td style="width:278px">Cough</td></tr><tr><td colspan="2" style="width:294px">Gastrointestinal disorders</td></tr><tr><td style="width:294px">Uncommon</td><td style="width:278px">Nausea, Diarrhoea</td></tr><tr><td style="width:294px">Hepato-biliary disorders</td><td style="width:278px">&nbsp;</td></tr><tr><td style="width:294px">Not known</td><td style="width:278px">Elevation of liver function values</td></tr><tr><td style="width:294px">Skin and subcutaneous tissue disorders</td><td style="width:278px">&nbsp;</td></tr><tr><td style="width:294px">Uncommon</td><td style="width:278px">Angioedema</td></tr><tr><td style="width:294px">Not known</td><td style="width:278px">Rash, Pruritis</td></tr><tr><td style="width:294px">Musculoskeletal and connective tissue disorders</td><td style="width:278px">&nbsp;</td></tr><tr><td style="width:294px">Not known</td><td style="width:278px">Myalgia</td></tr><tr><td style="width:294px">Renal and urinary disorders</td><td style="width:278px">&nbsp;</td></tr><tr><td style="width:294px">Common</td><td style="width:278px">Renal failure and impairment</td></tr><tr><td style="width:294px">Uncommon</td><td style="width:278px">Acute renal failure, Elevation of serum creatinine</td></tr><tr><td style="width:294px">Not known</td><td style="width:278px">Increase in Blood Urea Nitrogen</td></tr><tr><td style="width:294px">General disorders and administration site conditions</td><td style="width:278px">&nbsp;</td></tr><tr><td style="width:294px">Uncommon</td><td style="width:278px">Asthenia, Fatigue</td></tr></tbody></table><p>Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.<br />To reports any side effect (s):</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td>The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />o Toll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc</td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms</p><p>Overdose&nbsp;with valsartan&nbsp;may result&nbsp;in marked&nbsp;hypotension, which could lead to depressed level of consciousness, circulatory collapse and/or shock.</p><p>Treatment<br />The therapeutic measures depend on the time of ingestion and the type and severity of the symptoms; stabilisation of the circulatory condition is of prime importance.<br />If hypotension occurs, the patient should be placed in a supine position and blood volume correction should be undertaken.<br />Valsartan is unlikely to be removed by haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group:&nbsp;Angiotensin II Antagonists, plain, ATC code: C09CA03<br />Valsartan is an orally active, potent, and specific angiotensin II (Ang II) receptor antagonist. It acts selectively on the AT1 receptor subtype, which is responsible for the known actions of angiotensin II. The increased plasma levels of Ang II following AT1 receptor blockade with valsartan may stimulate the unblocked AT2 receptor, which appears to counterbalance the effect of the AT1 receptor. Valsartan does not exhibit any partial agonist activity at the AT1 receptor and has much (about 20,000 fold) greater affinity for the AT1 receptor than for the AT2 receptor. Valsartan is not known to bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation.</p><p>Valsartan does not inhibit ACE (also known as kininase II) which converts Ang I to Ang II and degrades bradykinin. Since there is no effect on ACE and no potentiation of bradykinin or substance P, angiotensin II antagonists are unlikely to be associated with coughing. In clinical trials where valsartan was compared with an ACE inhibitor, the incidence of dry cough was&nbsp;significantly (P&lt;0.05) less in patients treated with valsartan than in those treated with an ACE inhibitor (2.6% versus 7.9% respectively). In a clinical trial of patients with a history of dry cough during ACE inhibitor therapy, 19.5% of trial subjects receiving valsartan and 19.0% of those receiving a thiazide diuretic experienced cough compared to 68.5% of those treated with an ACE inhibitor (P&lt;0.05).</p><p>Recent myocardial infarction<br />The VALsartan In Acute myocardial Infarction trial (VALIANT) was a randomised, controlled, multinational, double-blind study in 14,703 patients with acute myocardial infarction and signs, symptoms or radiological evidence of congestive heart failure and/or evidence of left ventricular systolic dysfunction (manifested as an ejection fraction &le;40% by&nbsp;radionuclide ventriculography or &le;35% by echocardiography or ventricular contrast angiography). Patients were randomised within 12 hours to 10 days after the onset of myocardial infarction symptoms to valsartan, captopril, or the combination of both. The mean treatment duration was two years. The primary endpoint was time to all-cause mortality.<br />Valsartan was as effective as captopril in reducing all-cause mortality after myocardial infarction. All-cause mortality was similar in the valsartan (19.9%), captopril (19.5%), and valsartan + captopril (19.3%) groups. Combining valsartan with captopril did not add further benefit over captopril alone. There was no difference between valsartan and captopril in all-cause mortality based on age, gender, race, baseline therapies or underlying disease. Valsartan was also effective in prolonging the time to and reducing cardiovascular mortality, hospitalisation for heart failure, recurrent myocardial infarction, resuscitated cardiac arrest, and non-fatal stroke (secondary composite endpoint).</p><p>The safety profile of valsartan was consistent with the clinical course of patients treated in the post-myocardial infarction setting. Regarding renal function, doubling of serum creatinine was observed in 4.2% of valsartan-treated patients, 4.8% of valsartan+captopril-treated patients, and 3.4% of captopril-treated patients. Discontinuations due to various types of renal dysfunction occurred in 1.1% of valsartan-treated patients, 1.3% in valsartan+captopril patients, and 0.8% of captopril patients. An assessment of renal function should be included in the evaluation of patients post-myocardial infarction.<br />There was no difference in all-cause mortality, cardiovascular mortality or morbidity when beta blockers were administered together with the combination of valsartan + captopril, valsartan alone, or captopril alone. Irrespective of treatment, mortality was lower in the group of patients treated with a beta blocker, suggesting that the known beta blocker benefit in this population was maintained in this trial.</p><p>Heart failure<br />Val-HeFT was a randomised, controlled, multinational clinical trial of valsartan compared with placebo on morbidity and mortality in 5,010 NYHA class II (62%), III (36%) and IV (2%) heart failure patients receiving usual therapy with LVEF &lt;40% and left ventricular internal diastolic diameter (LVIDD) &gt; 2.9 cm/m<sup>2</sup>.&nbsp;Baseline therapy included ACE inhibitors (93%), diuretics (86%), digoxin (67%) and beta blockers (36%). The mean duration of follow-up was nearly two years. The mean daily dose of valsartan in Val-HeFT was 254mg. The study had two primary endpoints: all cause mortality (time to death) and composite mortality and heart failure morbidity (time to first morbid event) defined as death, sudden death with resuscitation,</p><p>hospitalisation for heart failure, or administration of intravenous inotropic or vasodilator agents for four hours or more without hospitalisation.</p><p>All cause mortality was similar (p=NS) in the valsartan (19.7%) and placebo (19.4%) groups. The primary benefit was a 27.5% (95% CI: 17 to 37%) reduction in risk for time to first heart&nbsp;failure hospitalisation (13.9% vs. 18.5%). Results appearing to favour placebo (composite mortality and morbidity was 21.9% in placebo vs. 25.4% in valsartan group) were observed for those patients receiving the triple combination of an ACE inhibitor, a beta blocker and valsartan.</p><p>In a subgroup of patients not receiving an ACE inhibitor (n=366), the morbidity benefits were greatest. In this subgroup all-cause mortality was significantly reduced with valsartan compared to placebo by 33% (95% CI: &ndash;6% to 58%) (17.3% valsartan vs. 27.1% placebo) and the composite mortality and morbidity risk was significantly reduced by 44% (24.9% valsartan vs. 42.5% placebo).</p><p>In patients receiving an ACE inhibitor without a beta-blocker, all cause mortality was similar (p=NS) in the valsartan (21.8%) and placebo (22.5%) groups. Composite mortality and morbidity risk was significantly reduced by 18.3% (95% CI: 8% to 28%) with valsartan compared with placebo (31.0% vs. 36.3%).<br />In the overall Val-HeFT population, valsartan treated patients showed significant improvement in NYHA class, and heart failure signs and symptoms, including dyspnoea, fatigue, oedema and rales compared to placebo. Patients treated with valsartan had a better quality of life as demonstrated by change in the Minnesota Living with Heart Failure Quality of Life score from baseline at endpoint than placebo. Ejection fraction in valsartan treated patients was significantly increased and LVIDD significantly reduced from baseline at endpoint compared to placebo.</p><p>Hypertension<br />Administration of valsartan to patients with hypertension results in reduction of blood pressure without affecting pulse rate.<br />In most patients, after administration of a single oral dose, onset of antihypertensive activity occurs within 2 hours, and the peak reduction of blood pressure is achieved within 4-6 hours. The antihypertensive effect persists over 24 hours after dosing. During repeated dosing, the antihypertensive effect is substantially present within 2 weeks, and maximal effects are attained within 4 weeks and persist during long-term therapy. Combined with hydrochlorothiazide, a significant additional reduction in blood pressure is achieved.<br />Abrupt withdrawal of valsartan has not been associated with rebound hypertension or other adverse clinical events.</p><p>In hypertensive patients with type 2 diabetes and microalbuminuria, valsartan has been shown to reduce the urinary excretion of albumin. The MARVAL (Micro Albuminuria Reduction with Valsartan) study assessed the reduction in urinary albumin excretion (UAE) with valsartan (80-160mg/od) versus amlodipine (5-10mg/od), in 332 type 2 diabetic patients (mean age: 58 years; 265 men) with microalbuminuria (valsartan: 58 &mu;g/min; amlodipine: 55.4&nbsp;&mu;g/min), normal or high blood pressure and with preserved renal function (blood creatinine &lt;120 &mu;mol/l). At 24 weeks, UAE was reduced (p&lt;0.001) by 42% (&ndash;24.2 &mu;g/min; 95% CI: &ndash;&nbsp;40.4 to &ndash;19.1) with valsartan and approximately 3% (&ndash;1.7 &mu;g/min; 95% CI: &ndash;5.6 to 14.9) with amlodipine despite similar rates of blood pressure reduction in both groups.</p><p>The Diovan Reduction of Proteinuria (DROP) study further examined the efficacy of valsartan in reducing UAE in 391 hypertensive patients (BP=150/88 mmHg) with type 2 diabetes, albuminuria (mean=102 &mu;g/min; 20-700 &mu;g/min) and preserved renal function (mean serum creatinine = 80 &mu;mol/l). Patients were randomized to one of 3 doses of valsartan (160, 320 and 640mg/od) and treated for 30 weeks. The purpose of the study was to determine the optimal dose of valsartan for reducing UAE in hypertensive patients with type 2 diabetes. At 30 weeks, the percentage change in UAE was significantly reduced by 36% from baseline with valsartan 160mg (95%CI: 22 to 47%), and by 44% with valsartan 320mg (95%CI: 31 to 54%). It was concluded that 160-320mg of valsartan produced clinically relevant reductions in UAE in hypertensive patients with type 2 diabetes.</p><p>Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker.<br />ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.<br />These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as compared to monotherapy was observed. Given their similar pharmacodynamic properties, these results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers.</p><p>ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in patients with diabetic nephropathy.<br />ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group than in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.<br />Paediatric population<br />Hypertension<br />The antihypertensive effect of valsartan have been evaluated in four randomized, double-blind clinical studies in 561 paediatric patients from 6 to 18 years of age and 165 paediatric patients 1 to 6 years of age. Renal and urinary disorders, and obesity were the most common underlying medical conditions potentially contributing to hypertension in the children enrolled in these studies.</p><p>Clinical experience in children at or above 6 years of age<br />In a clinical study involving 261 hypertensive paediatric patients 6 to 16 years of age, patients who weighed &lt;35 kg received 10, 40 or 80 mg of valsartan film coated tablets daily (low, medium and high doses), and patients who weighed &ge;35kg received 20, 80, and 160 mg of&nbsp;valsartan film coated tablets daily (low, medium and high doses). At the end of 2 weeks, valsartan reduced both systolic and diastolic blood pressure in a dose-dependent manner. Overall, the three dose levels of valsartan (low, medium and high) significantly reduced systolic blood pressure by 8, 10, 12 mm Hg from the baseline, respectively. Patients were re-randomized to either continue receiving the same dose of valsartan or were switched to placebo. In patients who continued to receive the medium and high doses of valsartan, systolic blood pressure at trough was -4 and -7 mm Hg lower than patients who received the placebo treatment. In patients receiving the low dose of valsartan, systolic blood pressure at trough was similar to that of patients who received the placebo treatment. Overall, the dose dependent antihypertensive effect of valsartan was consistent across all the demographic subgroups.<br />In another clinical study involving 300 hypertensive paediatric patients 6 to 18 years of age, eligible patients were randomized to receive valsartan or enalapril tablets for 12 weeks.</p><p>Children weighing between &ge;18 kg and &lt;35 kg received valsartan 80 mg or enalapril 10 mg; those between &ge;35 kg and &lt;80 kg received valsartan 160 mg or enalapril 20 mg; those &ge;80 kg received valsartan 320 mg or enalapril 40 mg. Reductions in systolic blood pressure were comparable in patients receiving valsartan (15 mmHg) and enalapril (14 mm Hg) (non-inferiority p-value &lt;0.0001). Consistent results were observed for diastolic blood pressure with reductions of 9.1 mmHg and 8.5 mmHg with valsartan and enalapril, respectively.<br />Clinical experience in children less than 6 years of age<br />Two clinical studies were conducted in patients aged 1 to 6 years with 90 and 75 patients, respectively. No children below the age of 1 year were enrolled in these studies. In the first study, the efficacy of valsartan was confirmed compared to placebo but a dose-response could not be demonstrated. In the second study, higher doses of valsartan were associated with greater BP reductions, but the dose response trend did not achieve statistical significance and the treatment difference compared to placebo was not significant. Because of these inconsistencies, valsartan is not recommended in this age group (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption:<br />Following oral administration of valsartan alone, peak plasma concentrations of valsartan are reached in 2-4 hours. Mean absolute bioavailability is 23%. Food decreases exposure (as measured by AUC) to valsartan by about 40% and peak plasma concentration (Cmax) by about&nbsp;50%, although from about 8 h post dosing plasma valsartan concentrations are similar for the fed and fasted groups. This reduction in AUC is not, however, accompanied by a clinically significant reduction in the therapeutic effect, and valsartan can therefore be given either with or without food.<br />Distribution:</p><p>The steady-state volume of distribution of valsartan after intravenous administration is about&nbsp;17 litres, indicating that valsartan does not distribute into tissues extensively. Valsartan is highly bound to serum proteins (94-97%), mainly serum albumin.</p><p>Biotransformation:<br />Valsartan is not biotransformed to a high extent as only about 20% of dose is recovered as metabolites. A hydroxy metabolite has been identified in plasma at low concentrations (less than 10% of the valsartan AUC). This metabolite is pharmacologically inactive.<br />Excretion:<br />Valsartan shows multiexponential decay kinetics (t&frac12;&alpha; &lt;1 h and t&frac12;&szlig; about 9 h). Valsartan is primarily eliminated by biliary excretion in faeces (about 83% of dose) and renally in urine (about 13% of dose), mainly as unchanged drug. Following intravenous administration, plasma clearance of valsartan is about 2 l/h and its renal clearance is 0.62 l/h (about 30% of total clearance). The half-life of valsartan is 6 hours.</p><p>In heart failure patients:<br />The average time to peak concentration and elimination half-life of valsartan in heart failure patients are similar to that observed in healthy volunteers. AUC and Cmax values of valsartan are almost proportional with increasing dose over the clinical dosing range (40 to 160mg twice a day). The average accumulation factor is about 1.7. The apparent clearance of valsartan following oral administration is approximately 4.5 l/h. Age does not affect the apparent clearance in heart failure patients.</p><p>Special populations<br />Elderly<br />A somewhat higher systemic exposure to valsartan was observed in some elderly subjects than in young subjects; however, this has not been shown to have any clinical significance.<br />Impaired renal function<br />As expected for a compound where renal clearance accounts for only 30% of total plasma clearance, no correlation was seen between renal function and systemic exposure to valsartan. Dose adjustment is therefore not required in patients with renal impairment (creatinine clearance &gt;10 ml/min). There is currently no experience on the safe use in patients with a creatinine clearance &lt; 10 ml/min and patients undergoing dialysis, therefore valsartan should be used with caution in these patients (see sections 4.2 and 4.4). Valsartan is highly bound to plasma protein and is unlikely to be removed by dialysis.</p><p>Hepatic impairment</p><p>Approximately 70% of the dose absorbed is eliminated in the bile, essentially in the unchanged form. Valsartan does not undergo any noteworthy biotransformation. A doubling of exposure (AUC) was observed in patients with mild to moderate hepatic impairment compared to healthy subjects. However, no correlation was observed between plasma valsartan concentration versus degree of hepatic dysfunction. Valsartan has not been studied in patients with severe hepatic dysfunction (see sections 4.2, 4.3 and 4.4).</p><p>Paediatric population<br />In a study of 26 paediatric hypertensive patients (aged 1 to 16 years) given a single dose of a suspension of valsartan (mean: 0.9 to 2 mg/kg, with a maximum dose of 80 mg), the clearance&nbsp;(litres/h/kg) of valsartan was comparable across the age range of 1 to 16 years and similar to that of adults receiving the same formulation.<br />Impaired renal function<br />Use in paediatric patients with a creatinine clearance &lt;30 ml/min and paediatric patients undergoing dialysis has not been studied, therefore valsartan is not recommended in these patients. No dose adjustment is required for paediatric patients with a creatinine clearance &gt;30 ml/min. Renal function and serum potassium should be closely monitored (see sections 4.2 and 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential.<br />In rats, maternally toxic doses (600mg/kg/day) during the last days of gestation and lactation led to lower survival, lower weight gain and delayed development (pinna detachment and ear-canal opening) in the offspring (see section 4.6). These doses in rats (600mg/kg/day) are approximately 18 times the maximum recommended human dose on a mg/m2 basis (calculations assume an oral dose of 320mg/day and a 60-kg patient).<br />In non-clinical safety studies, high doses of valsartan (200 to 600mg/kg body weight) caused in rats a reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit) and evidence of changes in renal haemodynamics (slightly raised plasma urea, and renal tubular hyperplasia and basophilia in males). These doses in rats (200 and 600mg/kg/day) are approximately 6 and 18 times the maximum recommended human dose on a mg/m2 basis (calculations assume an oral dose of 320mg/day and a 60-kg patient).<br />In marmosets at similar doses, the changes were similar though more severe, particularly in the kidney where the changes developed to a nephropathy which included raised urea and creatinine.</p><p>Hypertrophy of the renal juxtaglomerular cells was also seen in both species. All changes were considered to be caused by the pharmacological action of valsartan which produces prolonged&nbsp;hypotension, particularly in marmosets. For therapeutic doses of valsartan in humans, the hypertrophy of the renal juxtaglomerular cells does not seem to have any relevance.</p><p>Paediatric population<br />Daily oral dosing of neonatal/juvenile rats (from a postnatal day 7 to postnatal day 70) with valsartan at doses as low as 1 mg/kg/day (about 10-35% of the maximum recommended paediatric dose of 4 mg/kg/day on systemic exposure basis) produced persistent, irreversible kidney damage. These effects above mentioned represent an expected exaggerated pharmacological effect of angiotensin converting enzyme inhibitors and angiotensin II type 1 blockers; such effects are observed if rats are treated during the first 13 days of life.<br />This period coincides with 36 weeks of gestation in humans, which could occasionally extend up to 44 weeks after conception in humans. The rats in the juvenile valsartan study were dosed up to day 70, and effects on renal maturation (postnatal 4-6 weeks) cannot be excluded. Functional renal maturation is an ongoing process within the first year of life in humans. Consequently, a clinical relevance in children &lt;1 year of age cannot be excluded, while preclinical data do not indicate a safety concern for children older than 1 year.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Microcrystalline Cellulose</p><p>Crospovidone</p><p>Talc</p><p>Colloidal silicone dioxide</p><p>Magnesium stearate</p><p>Sepifilm</p><p>Titanium dioxide</p><p>Red iron oxide</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Primary packaging material:<br />Aluminum /Aluminum foil blister pack.<br />Secondary packaging material:<br />Printed cardboard case containing the blister packs and the package insert.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jordan Sweden Medical and Sterilization Company (JOSWE-medical)
P.O. Box 851831 Amman 11185 Jordan
E-mail: joswe@go.com.jo
Tel: +962 6 5859765 - + 962 6 5728327
Fax: +962 6 5814526 - +962 6 5728326
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                10/2015
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>